Abstract 9331: Hospitalizations and Mortality Trends in Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis and Cardiovascular Diseases in the United States, 2016-2022
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Yussif Issaka und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading chronic liver disease in the United States, and cardiovascular disease (CVD) is its major extrahepatic cause of morbidity and mortality. However, the burden and impact of coexisting CVD among hospitalized patients with MASLD cirrhosis remain poorly defined. Hypothesis: Coexisting CVD is increasingly prevalent among hospitalized patients with MASLD cirrhosis and is independently associated with worse inpatient outcomes, greater healthcare utilization, and a higher burden of major adverse cardiovascular events (MACE).
Methods
We analyzed adult MASLD cirrhosis hospitalizations in the National Inpatient Sample (2016-2022). CVD included coronary artery disease, heart failure, atrial fibrillation/flutter, stroke, peripheral vascular disease, or pulmonary arterial hypertension. Primary outcomes were in-hospital mortality and MACE. Secondary outcomes included acute kidney injury, sepsis, shock, mechanical ventilation, hemodialysis, liver transplantation, length of stay (LOS), and hospital charges. Survey-weighted multivariable logistic regression adjusted for demographic, socioeconomic, hospital, and comorbidity factors. Temporal trends were assessed using Cochran-Armitage tests.
Results
Among 116,589 MASLD cirrhosis hospitalizations, representing 582,945 weighted admissions, 50.3% had coexisting CVD. Patients with CVD were older, more often male, and had greater comorbidity burden (all p
Zitieren
APA
Issaka, Y., Boateng, S., Gyabaah, S., Tchoukeu, G. L. N., Al-Ajlouni, Y., & Njei, B. (2026). Abstract 9331: Hospitalizations and Mortality Trends in Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis and Cardiovascular Diseases in the United States, 2016-2022. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9331
Vancouver
Issaka Y, Boateng S, Gyabaah S, Tchoukeu GLN, Al-Ajlouni Y, Njei B. Abstract 9331: Hospitalizations and Mortality Trends in Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis and Cardiovascular Diseases in the United States, 2016-2022. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9331
BibTeX
@article{Issaka2026,
author = {Issaka, Yussif and Boateng, Sarpong and Gyabaah, Solomon and Tchoukeu, Guy Loic Nguefang and Al-Ajlouni, Yazan and Njei, Basile},
title = {Abstract 9331: Hospitalizations and Mortality Trends in Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis and Cardiovascular Diseases in the United States, 2016-2022},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9331}
}
EUVIMED